Sex: U
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: No adverse event; Adult patient (Not pregnant) received expired Bivalent Blue Cap booster doses of Moderna COVID-19 vaccine on 10-JUN-2023 through 24-JUN-2023/Dose administered after 30-day Use By Date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Adult patient (Not pregnant) received expired Bivalent Blue Cap booster doses of Moderna COVID-19 vaccine on 10-JUN-2023 through 24-JUN-2023/Dose administered after 30-day Use By Date) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7642B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 10-Jun-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 10-Jun-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (Adult patient (Not pregnant) received expired Bivalent Blue Cap booster doses of Moderna COVID-19 vaccine on 10-JUN-2023 through 24-JUN-2023/Dose administered after 30-day Use By Date). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Adult patient (Not pregnant) received expired Bivalent Blue Cap booster doses of Moderna COVID-19 vaccine on 10-JUN-2023 through 24-JUN-2023/Dose administered after 30-day Use By Date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Adult patient (Not pregnant) received expired Bivalent Blue Cap booster doses of Moderna COVID-19 vaccine on 10-JUN-2023 through 24-JUN-2023/Dose administered after 30-day Use By Date).    No concomitant information was reported. None of the patients were pregnant. Suspect product dosage text was reported as unknown. The 2.5 ml vial was initially stored in the refrigerator on 10-MAY-2023 and did not underwent any temperature excursions. No treatment information was provided. This case is reported for patient 1 out of 9 patients.   This case was linked to MOD-2023-732805, US-MODERNATX, INC.-MOD-2023-732813, US-MODERNATX, INC.-MOD-2023-732815, US-MODERNATX, INC.-MOD-2023-732821, US-MODERNATX, INC.-MOD-2023-732833, US-MODERNATX, INC.-MOD-2023-732835, US-MODERNATX, INC.-MOD-2023-732837, US-MODERNATX, INC.-MOD-2023-732834 (E2B Linked Report).; Sender's Comments:  MOD-2023-732805:Master case Patient 1 US-MODERNATX, INC.-MOD-2023-732813:Same report Patient 2 US-MODERNATX, INC.-MOD-2023-732821:Same report Patient 4 US-MODERNATX, INC.-MOD-2023-732815:Same report Patient 3 US-MODERNATX, INC.-MOD-2023-732837:Same report Patient 9 US-MODERNATX, INC.-MOD-2023-732833:Same report Patient 6 US-MODERNATX, INC.-MOD-2023-732835:Same report Patient 8 US-MODERNATX, INC.-MOD-2023-732834:Same report Patient 7